Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes

Journal of Diabetes Research

Volumn 2018, Issue , 2018, Pages

  Tavira, Beatriz ^a   Barcenilla, Hugo ^a   Wahlberg, Jeannette ^a   Achenbach, Peter ^b   Ludvigsson, Johnny ^a,c   Casas, Rosaura ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Crown Princess Victoria Children's Hospital   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; AUTOANTIBODY; BIOLOGICAL MARKER; C PEPTIDE; CD4 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOKINE; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE 65; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 5; INTERLEUKIN 7 RECEPTOR; PLACEBO; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; VITAMIN D; ALUMINUM SULFATE; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 2; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; T LYMPHOCYTE ACTIVATION; TH2 CELL; TREATMENT RESPONSE; YOUNG ADULT; CHILD; CLINICAL TRIAL; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; TREATMENT OUTCOME;

ADOLESCENT; ALUM COMPOUNDS; CELL PROLIFERATION; CHILD; CYTOKINES; DIABETES MELLITUS, TYPE 1; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNOGLOBULIN G; IMMUNOMODULATION; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; LYMPHOCYTE ACTIVATION; MALE; PILOT PROJECTS; TH2 CELLS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85058704825     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2018/9391845     Document Type: Article

References (40)

1. N. C. Schloot, G. Meierhoff, C. Lengyel et al., "Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials," Diabetes/Metabolism Research and Reviews, vol. 23, no. 4, pp. 276-285, 2007.
2. B. Keymeulen, E. Vandemeulebroucke, A. G. Ziegler et al., "Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes," New England Journal of Medicine, vol. 352, no. 25, pp. 2598-2608, 2005.
3. K. C. Herold, W. Hagopian, J. A. Auger et al., "Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus," New England Journal of Medicine, vol. 346, no. 22, pp. 1692-1698, 2002.
4. M. D. Pescovitz, C. J. Greenbaum, H. Krause-Steinrauf et al., "Rituximab, B-lymphocyte depletion, and preservation of beta-cell function," New England Journal of Medicine, vol. 361, no. 22, pp. 2143-2152, 2009.
5. T. Orban, B. Bundy, D. J. Becker et al., "Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial," The Lancet, vol. 378, no. 9789, pp. 412-419, 2011.
6. P. Pozzilli, D. Pitocco, N. Visalli et al., "No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB group," Diabetologia, vol. 43, no. 8, pp. 1000-1004, 2000.
7. M. Walter, A. Philotheou, F. Bonnici, A.-G. Ziegler, R. Jimenez, and on behalf of the NBI-6024 Study Group, "No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes," Diabetes Care, vol. 32, no. 11, pp. 2036-2040, 2009.
8. J. Ludvigsson, M. Faresjö, M. Hjorth et al., "GAD treatment and insulin secretion in recent-onset type 1 diabetes," New England Journal of Medicine, vol. 359, no. 18, pp. 1909-1920, 2008.
9. D. K. Wherrett, B. Bundy, D. J. Becker et al., "Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial," The Lancet, vol. 378, no. 9788, pp. 319-327, 2011.
10. J. Ludvigsson, D. Krisky, R. Casas et al., "GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus," New England Journal of Medicine, vol. 366, no. 5, pp. 433-442, 2012.
11. B. Tavira, M. Cheramy, S. Axelsson, L. Akerman, J. Ludvigsson, and R. Casas, "Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD65-induced immune response," Diabetologia, vol. 60, no. 7, pp. 1276-1283, 2017.
12. C. A. Beam, the Type 1 Diabetes TrialNet Study Group, C. MacCallum et al., "GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis," Diabetologia, vol. 60, no. 1, pp. 43-49, 2017.
13. O. Pfaar, C. Bachert, A. Bufe et al., "Guideline on allergenspecific immunotherapy in IgE-mediated allergic diseases," Allergo Journal International, vol. 23, no. 8, pp. 282-319, 2014.
14. S. Dhami, U. Nurmatov, G. B. Pajno et al., "Allergen immunotherapy for IgE-mediated food allergy: protocol for a systematic review," Clinical and Translational Allergy, vol. 6, no. 1, p. 24, 2016.
15. S. Tsabouri, A. Mavroudi, G. Feketea, and G. V. Guibas, "Subcutaneous and sublingual immunotherapy in allergic asthma in children," Frontiers in Pediatrics, vol. 5, p. 82, 2017.
16. Y. Chelladurai, C. Suarez-Cuervo, N. Erekosima et al., "Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review," The Journal of Allergy and Clinical Immunology: In Practice, vol. 1, no. 4, pp. 361-369, 2013.
17. K. J. Maloy, I. Erdmann, V. Basch et al., "Intralymphatic immunization enhances DNA vaccination," Proceedings of the National Academy of Sciences, vol. 98, no. 6, pp. 3299-3303, 2001.
18. G. Senti, B. M. Prinz Vavricka, I. Erdmann et al., "Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial," Proceedings of the National Academy of Sciences, vol. 105, no. 46, pp. 17908-17912, 2008.
19. A. M. Patterson, A. E. Bonny, W. E. Shiels II, and E. A. Erwin, "Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis," Annals of Allergy, Asthma & Immunology, vol. 116, no. 2, pp. 168-170, 2016.
20. T. Hylander, O. Larsson, U. Petersson-Westin et al., "Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial," Respiratory Research, vol. 17, no. 1, p. 10, 2016.
21. G. Senti, R. Crameri, D. Kuster et al., "Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections," Journal of Allergy and Clinical Immunology, vol. 129, no. 5, pp. 1290-1296, 2012.
22. A. Mackensen, T. Krause, U. Blum, P. Uhrmeister, R. Mertelsmann, and A. Lindemann, "Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells," Cancer Immunology, Immunotherapy, vol. 48, no. 2-3, pp. 118-122, 1999.
23. P. Johansen, A. . C. Häffner, F. Koch et al., "Direct intralymphatic injection of peptide vaccines enhances immunogenicity," European Journal of Immunology, vol. 35, no. 2, pp. 568-574, 2005.
24. J. Ludvigsson, J. Wahlberg, and R. Casas, "Intralymphatic injection of autoantigen in type 1 diabetes," New England Journal of Medicine, vol. 376, no. 7, pp. 697-699, 2017.
25. J. Ludvigsson, B. Tavira, and R. Casas, "More on intralymphatic injection of autoantigen in type 1 diabetes," New England Journal of Medicine, vol. 377, no. 4, pp. 403-405, 2017.
26. M. Cheramy, C. Skoglund, I. Johansson, J. Ludvigsson, C. S. Hampe, and R. Casas, "GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response," Clinical Immunology, vol. 137, no. 1, pp. 31-40, 2010.
27. E. Bonifacio, M. Scirpoli, K. Kredel, M. Füchtenbusch, and A. G. Ziegler, "Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation," Journal of Immunology, vol. 163, no. 1, pp. 525-532, 1999.
28. S. Axelsson, M. Cheramy, L. Akerman, M. Pihl, J. Ludvigsson, and R. Casas, "Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GADalum intervention trial," Diabetes Care, vol. 36, no. 11, pp. 3418-3424, 2013.
29. S. Axelsson, M. Chéramy, M. Hjorth et al., "Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes," PLoS One, vol. 6, no. 12, article e29008, 2011.
30. L. C. Harrison, M. C. Honeyman, C. E. Steele et al., "Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes," Diabetes Care, vol. 27, no. 10, pp. 2348-2355, 2004.
31. M. A. Russell, A. C. Cooper, S. Dhayal, and N. G. Morgan, "Differential effects of interleukin-13 and interleukin-6 on Jak/STAT signaling and cell viability in pancreatic ?-cells," Islets, vol. 5, no. 2, pp. 95-105, 2013.
32. L. Usero, A. Sánchez, E. Pizarro et al., "Interleukin-13 pathway alterations impair invariant natural killer T-cell-mediated regulation of effector T cells in type 1 diabetes," Diabetes, vol. 65, no. 8, pp. 2356-2366, 2016.
33. K. J. Wood and B. Sawitzki, "Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo," Trends in Immunology, vol. 27, no. 4, pp. 183-187, 2006.
34. J. Fenimore and H. A. Young, "Regulation of IFN-? expression," Advances in Experimental Medicine and Biology, vol. 941, pp. 1-19, 2016.
35. M. Pihl, H. Barcenilla, S. Axelsson et al., "GAD-specific T cells are induced by GAD-alum treatment in type-1 diabetes patients," Clinical Immunology, vol. 176, pp. 114-121, 2017.
36. M. Hjorth, S. Axelsson, A. Ryden, M. Faresjo, J. Ludvigsson, and R. Casas, "GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients," Clinical Immunology, vol. 138, no. 1, pp. 117-126, 2011.
37. M. Pihl, L. Åkerman, S. Axelsson et al., "Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes," Clinical & Experimental Immunology, vol. 172, no. 3, pp. 394-402, 2013.
38. S. Schmid, A. Molteni, M. Fuchtenbusch, H. E. Naserke, A. G. Ziegler, and E. Bonifacio, "Reduced IL-4 associated antibody responses to vaccine in early pre-diabetes," Diabetologia, vol. 45, no. 5, pp. 677-685, 2002.
39. J. M. Martinez-Gomez, P. Johansen, I. Erdmann, G. Senti, R. Crameri, and T. M. Kundig, "Intralymphatic injections as a new administration route for allergen-specific immunotherapy," International Archives of Allergy and Immunology, vol. 150, no. 1, pp. 59-65, 2009.
40. J. M. Brewer, M. Conacher, C. A. Hunter, M. Mohrs, F. Brombacher, and J. Alexander, "Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4-or IL-13-mediated signaling," Journal of Immunology, vol. 163, no. 12, pp. 6448-6454, 1999.